CJC-1295 DAC

CJC-1295 DAC is the long-acting form of CJC-1295, with an added Drug Affinity Complex (a maleimido-propionic acid linker) that covalently binds serum albumin, extending the half-life from minutes to roughly 6–8 days.

CJC-1295 DAC is the 'set it and forget it' GHRH analog. Instead of producing a sharp pulse, it raises baseline GH and IGF-1 for days at a time — which is exactly why it is loved by some researchers and avoided by others.

Same GHRH receptor binding as standard CJC-1295, but the DAC linker tethers it to circulating albumin, creating a depot that continuously stimulates the pituitary. The result is sustained elevation of GH and IGF-1 rather than discrete pulses.

GHRH analog with Drug Affinity Complex (DAC) attached. Half-life extends to ~8 days for sustained GH elevation.

1. CJC-1295 DAC
2. GHRH and/or ghrelin receptors in the pituitary
3. Pulsatile growth hormone release
4. Downstream IGF-1, body-composition and recovery endpoints

A plain-English read on how much published evidence currently exists for CJC-1295 DAC. These ratings describe the volume and maturity of the literature — not effectiveness, safety, or suitability for any use.

Current limitations: most compounds in this category are studied in preclinical or small-sample settings. Absence of large controlled human trials is the single biggest limitation to keep in mind when reading any summary of CJC-1295 DAC.

Lyophilized compounds are supplied as a dry powder. Concentration is simply the total amount in the vial divided by the volume of bacteriostatic water added:

Concentration (mg/mL) = total mg in vial ÷ mL of diluent added

Commonly supplied vial sizes

2mg or 5mg vial

Worked concentration example

2mg + 2mL BAC water → 1mg/mL On U-100 insulin syringe:

• • 10 units = 100mcg
• • 100 units = 1mg

Run your own numbers with the reconstitution calculator — it converts vial size and diluent volume into mg/mL and mcg/mL.

The figures below are reported here descriptively, because they are the values most frequently cited in publicly available research literature and reference material. They are not instructions, not a protocol, and not a recommendation. These compounds are supplied for laboratory research use only and are not approved by the FDA for human consumption.

Commonly cited amounts

1–2mg weekly (or 1mg twice weekly)

Commonly cited frequency

1–2× weekly

Commonly cited study duration

12–16 weeks

Peptides are supplied freeze-dried because peptide bonds degrade far faster in solution than in a dry state. Understanding storage is part of understanding why the powder form exists at all.

• •Lyophilized powder: stored refrigerated, typically stable for months to years.
• •Reconstituted solution: refrigerated at 2–8°C, generally discussed as stable for roughly 30–60 days.
• •Heat and direct light accelerate degradation — vials are kept cool and dark.
• •Reconstituted material is not re-frozen; ice crystal formation disrupts peptide structure.
• •Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which is what allows multi-day storage after reconstitution.

More detail in the storage & handling guide and how peptide quality is evaluated.

• •Sustained GH and IGF-1 elevation studies
• •Comparison with pulsatile GHRH analogs
• •Body composition and recovery research
• •Sleep architecture
• •Long-term anti-aging research models

Polarizing in research forums. Fans cite convenience and consistent IGF-1; critics argue that sustained elevation defeats the natural pulsatility that makes GHRH analogs attractive in the first place. Once-weekly dosing is the headline appeal.

“Always-on growth hormone, in one weekly shot.”

Sometimes stacked with Ipamorelin, though many researchers prefer no-DAC CJC + Ipamorelin to preserve pulsatility. Compared head-to-head with Tesamorelin and Sermorelin.

CJC-1295 DAC is the long-acting albumin-bound form of CJC-1295, studied for sustained GH/IGF-1 elevation with once-weekly research dosing.